Adiponectin Receptor Agonist Effectively Suppresses Hepatocellular Carcinoma Growth

Nguyen, Mai Ly Thi; Pham, Chi; Pham, Van Tran; Nham, Phuong Linh Thi; Ta, Ba Thang; Le, Dinh Tuan; Le, Quoc Vuong; Hoang, Xuan Cuong; Bozko, Przemyslaw; Nguyen, Linh Toan; Bui, Khac Cuong

doi:10.1007/s12013-024-01217-9

Cell Biochem Biophys

2024

DOI: 10.1007/s12013-024-01217-9

|View full text |Cite

Adiponectin Receptor Agonist Effectively Suppresses Hepatocellular Carcinoma Growth

Mai Ly Thi Nguyen,

Chi Pham,

Van Tran Pham

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Adipokines: masterminds of metabolic inflammation

Tilg,

Ianiro,

Gasbarrini

et al. 2024

Nat Rev Immunol

View full text Add to dashboard Cite

Adipokines: masterminds of metabolic inflammation

Tilg,

Ianiro,

Gasbarrini

et al. 2024

Nat Rev Immunol

View full text Add to dashboard Cite

Adiponectin Receptor Agonist AdipoRon Inhibits Proliferation and Drives Glycolytic Dependence in Non-Small-Cell Lung Cancer Cells

Kafeel,

Ragone,

Salzillo

et al. 2024

Cancers

View full text Add to dashboard Cite

Despite the countless therapeutic advances achieved over the years, non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide. To this primacy contribute both non-oncogene addicted and advanced NSCLCs, in which conventional therapies are only partially effective. The adiponectin receptor agonist AdipoRon has revealed antiproliferative action in different cancers, including osteosarcoma and pancreatic cancer. Herein, we investigated its potential anticancer role in NSCLC for the first time. We proved that AdipoRon strongly inhibits viability, growth and colony formation in H1299 and A549 NSCLC cells, mainly through a slowdown in cell cycle progression. Along with the biological behaviors, a metabolic switching was observed after AdipoRon administration in NSCLC cells, consisting of higher glucose consumption and lactate accumulation. Remarkably, both 2-Deoxy Glucose and Oxamate glycolytic-interfering agents greatly enhanced AdipoRon’s antiproliferative features. As a master regulator of cell metabolism, AMP-activated protein kinase (AMPK) was activated by AdipoRon. Notably, the ablation of AdipoRon-induced AMPK phosphorylation by Compound-C significantly counteracted its effectiveness. However, the engagement of other pathways should be investigated afterwards. With a focus on NSCLC, our findings further support the ability of AdipoRon in acting as an anticancer molecule, driving its endorsement as a future candidate in NSCLC therapy.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Adiponectin Receptor Agonist Effectively Suppresses Hepatocellular Carcinoma Growth

Cited by 2 publications

References 42 publications

Adipokines: masterminds of metabolic inflammation

Adipokines: masterminds of metabolic inflammation

Adiponectin Receptor Agonist AdipoRon Inhibits Proliferation and Drives Glycolytic Dependence in Non-Small-Cell Lung Cancer Cells

Contact Info

Product

Resources

About